Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 17/20 | 0.41 |
| ▸ | KDR | P35968 | 13/20 | 0.41 |
| ▸ | AXL | P30530 | 2/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.35 |
| ▸ | MST1R | Q04912 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2282426 | 0.92 | MET (0.36) | METKDRAXLNTRK1KIT | |
| SCHEMBL2285671 | 0.91 | MET (0.40) | METKDRAXLNTRK1KIT | |
| SCHEMBL2284158 | 0.91 | MET (0.39) | METKDRAXLNTRK1KIT | |
| SCHEMBL2287619 | 0.84 | MET (0.40) | METKDRAXLNTRK1KIT | |
| SCHEMBL12376890 | 0.84 | MET (0.53) | METKDRAXLNTRK1KIT | |
| SCHEMBL2285176 | 0.83 | MET (0.41) | METKDRAXLNTRK1KIT | |
| SCHEMBL2278505 | 0.81 | MET (0.36) | METKDRAXLNTRK1KIT | |
| SCHEMBL2282334 | 0.81 | MET (0.36) | METKDRAXLNTRK1KIT | |
| SCHEMBL2286372 | 0.81 | MET (0.44) | METKDRAXLMST1R | |
| SCHEMBL2285551 | 0.81 | MET (0.37) | METKDRAXLNTRK1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | MET 142/4885KDR 419/4885AXL 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.